Pinatuzumab vedotin
- Generic Name
- Pinatuzumab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1313706-14-7
- Unique Ingredient Identifier
- 6KA1906BLC
- Background
Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT01691898
- Locations
- 🇮🇹
Azienda Ospedale San Giovanni, Torino, Piemonte, Italy
🇺🇸Texas Oncology, P.A. - Tyler; Tyler Cancer Center, Tyler, Texas, United States
🇨🇦McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01209130
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath